Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0024-3205(78)90230-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Decitabine Increases the Transcription of Gene to Suppress the Replication of Feline Calicivirus and Canine Influenza Virus.
Microorganisms
January 2025
College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.
Developing novel antiviral drugs has always been a significant forefront in biological medicine research. Antiviral drugs can be extracted, purified, and synthesized from various biological sources and by different methods. However, they are less explored in veterinary medicine for animal viruses.
View Article and Find Full Text PDFLubiprostone Reduces Fat Content on MRI-PDFF in Patients With MASLD: A 48-Week Randomised Controlled Trial.
Aliment Pharmacol Ther
February 2025
Liver Unit, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
Article Synopsis
- A 48-week study was conducted to evaluate the safety and effectiveness of the laxative lubiprostone in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), showing promising results.
- Lubiprostone significantly reduced liver fat content compared to placebo, although it did not significantly impact fibrosis scores or serum ALT levels.
- While the treatment was generally tolerated, with only one case of severe diarrhea in the lubiprostone group, further research is needed to confirm its efficacy for MASLD.
Prostaglandin E1 administration post liver transplantation and renal outcomes: A retrospective single center experience.
World J Transplant
December 2024
Department of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI 48109, United States.
Background: Prostaglandin E1 (PGE1), or alprostadil, is a potent vasodilator that improves hepatic blood flow and reduces ischemia-reperfusion injury post-liver transplantation (LT). However, the benefits of PGE1 on renal function after LT have not yet been well described.
Aim: To assess the impact of PGE1 administration on renal function in patients who underwent liver or liver-kidney transplant.
Phosphodiesterase 5 and its inhibitors with ischemic heart disease: a Mendelian randomization analysis and a real-world study.
Eur Heart J Cardiovasc Pharmacother
October 2024
Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, Fujian, China.
Background: Accumulating studies reported that several phosphodiesterases (PDEs) inhibitors might have cardiovascular benefits.
Objectives: This study aimed to explore the relationship between genetically-predicted PDEs and ischemia heart disease via drug target Mendelian randomization (MR) approach, and then examine the effect of inhibitors of identified target on the outcomes by using real-world data.
Methods: In the two-sample MR study, the expression of genes encoding PDEs was used to proxy the level of PDEs and available expression quantitative trait loci (eQTLs) for each target gene were identified as the genetic instruments.
The colonic polyphenol catabolite dihydroferulic acid (DHFA) regulates macrophages activated by oxidized LDL, 7-ketocholesterol, and LPS switching from pro- to anti-inflammatory mediators.
Food Funct
October 2024
Vidarium - Nutrition, Health and Wellness Research Center, Nutresa Business Group, Calle 8 Sur No. 50-67, Medellin, Colombia.
Macrophage activation plays a central role in the development of atherosclerotic plaques. Interaction with oxidized low-density lipoprotein (oxLDL) leads to macrophage differentiation into foam cells and oxylipin production, contributing to plaque formation. 7-Ketocholesterol (7KC) is an oxidative byproduct of cholesterol found in oxLDL particles and is considered a factor contributing to plaque progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!